Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

Purpose Both nintedanib/docetaxel and anti‐PD‐1/PD‐L1 immunotherapies have demonstrated efficacy as second‐line treatment of patients with advanced lung adenocarcinoma. This is the first report on the efficacy of the nintedanib/docetaxel combination following first‐line platinum‐based chemotherapy a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical & translational oncology 2019-09, Vol.21 (9), p.1270-1279
Hauptverfasser:	Corral, J., Majem, M., Rodríguez-Abreu, D., Carcereny, E., Cortes, Á. A., Llorente, M., López Picazo, J. M., García, Y., Domine, M., López Criado, M P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma of Lung - drug therapy Adenocarcinoma of Lung - mortality Adenocarcinoma of Lung - pathology Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Docetaxel - administration & dosage Female Follow-Up Studies Humans Immunotherapy - mortality Indoles - administration & dosage Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Prognosis Research Article Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!